title: [Experimental study on intratumoral injection with hydroxyapatite bioceramics and adriamycin in implanted hepatoma in mice].
abstract: Hydroxyapatite (HA) bioceramics is a biomaterial used in orthopedic area. We observed its anticancer effect in experimental hepatoma-22 (H22) in mice. BALB/c mice implanted with H22 were grouped into I, II, III and IV. Intratumoral injections were given as follows: (I) HA 0.1 g and ADM 0.1 mg n = 28; (II) HA 0.1 g n = 16; (III) ADM 0.1 mg n = 16; (IV) untreated n = 20. The tumor regression rates of the groups I, II and III were 65.9%, 41.9% and 51.1%, respectively. The mean survivals of groups I, II, III and IV were 32, 22, 26 and 18 days. Six mice of group I were alive more than 50 days before being killed, in which 4 tumor samples showed that no residual tumor cells could be seen under microscope. The possible mechanism of HA anti-cancer action is: (1) the dissolved matter of HA, glycoprotein and microfibril around the tumor cells may disturb the metabolism of cancer; (2) fibrocalcific process restricts the tumor growth; (3) immunoenhancement action (4) as a drug-release system HA is a hopeful agent of intratumoral injection for treatment of cancer.
authors.forename: X
authors.initials: X
authors.lastname: Chen
authors.forename: Y
authors.initials: Y
authors.lastname: Wu
authors.forename: R
authors.initials: R
authors.lastname: Ran
authors.forename: X
authors.initials: X
authors.lastname: Meng
authors.forename: Y
authors.initials: Y
authors.lastname: Li
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006882:Hydroxyapatites / Q000008:administration & dosage; D015552:Injections, Intralesional; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D008863:Microspheres; D009368:Neoplasm Transplantation
chemical_list: D006882:Hydroxyapatites; D004317:Doxorubicin